NCIt definition : A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell
surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the
surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent
cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen,
a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel,
is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells
of B-cell origin; it plays an important role in B-cell functioning.;
UNII : A10SJL62JY;
CAS number : 637334-45-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 637334-45-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;